Statera Biopharma, Inc.: 10-Q filed 2021-08-16
What Statera Biopharma, Inc. reported in its quarterly report filed 2021-08-16 (fiscal Q2 2021): 28 published measures, 84 facts as tagged in accession 0001437749-21-019964.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-08-16
- Fiscal period
- fiscal Q2 2021
- Accession
- 0001437749-21-019964 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Statera Biopharma, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,828,734 | USD | |
| At 2020-12-31 | 2,318,021 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 300,623 | USD | |
| At 2020-12-31 | 304,611 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 8,569,489 | USD | |
| At 2020-12-31 | -2,960,055 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,776,955 | USD | |
| At 2020-12-31 | 1,946,418 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -659,506 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -1,197,604 | USD | 181 |
| 2020-04-01 to 2020-06-30 | -369,838 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -958,370 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | -1,223,547 | USD | 181 |
| 2020-01-01 to 2020-06-30 | -902,004 | USD | 182 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 0 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 0 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 63,255 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 219,297 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 12,723,288 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 3,165,640 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 323,111 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 43,245 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -170,301,633 | USD | |
| At 2020-12-31 | -169,104,029 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 0 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 0 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 0 | USD | 91 |
| 2020-01-01 to 2020-03-31 | 0 | USD | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 4,954 | USD | |
| At 2020-12-31 | 3,715 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -669,237 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -1,220,499 | USD | 181 |
| 2020-04-01 to 2020-06-30 | -592,191 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,036,523 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,823,780 | USD | |
| At 2020-12-31 | 2,314,306 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 60,503 | USD | |
| At 2020-12-31 | 167,773 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 0 | USD | |
| At 2020-12-31 | 11,512 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 669,237 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 1,220,499 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 655,446 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 1,255,820 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 51,515 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 169,773 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 170,007 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 388,215 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 15,468,945 | shares | |
| At 2020-12-31 | 13,376,062 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -681,820 | USD | |
| At 2020-12-31 | -685,680 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,528,111 | USD | |
| At 2021-03-31 | 14,181,607 | USD | |
| At 2020-12-31 | 2,013,410 | USD | |
| At 2020-06-30 | 3,291,902 | USD | |
| At 2020-03-31 | 779,364 | USD | |
| At 2019-12-31 | 984,286 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 240,120 | USD | |
| At 2020-12-31 | 136,838 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -667,094 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -1,214,299 | USD | 181 |
| 2021-01-01 to 2021-03-31 | -547,205 | USD | 90 |
| 2020-04-01 to 2020-06-30 | -376,545 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -978,273 | USD | 182 |
| 2020-01-01 to 2020-03-31 | -601,728 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -650,462 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -1,193,744 | USD | 181 |
| 2020-04-01 to 2020-06-30 | -339,455 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,002,464 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 617,722 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 1,050,726 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 485,439 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 867,605 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 3,077 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 5,928 | USD | 182 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 2,295 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 6,210 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 508,811 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 511,711 | USD | 182 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 2,143 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 6,200 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 215,646 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 58,250 | USD | 182 |
Inspect the source
- Entity
- Statera Biopharma, Inc. / CIK 0001318641
- Captured
- SEC response SHA-256
9e499247f86d1cf9ca87ba87bfcdf37d42baa7907f4baa6e983f1992a49045f7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001318641.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))